Author:
Tsuda Yoshiyuki,Matsuo Yumiko,Matsumoto Sayaka,Wajima Toshihiro
Funder
Shionogi & Co., Ltd.
Shire International GmbH
Takeda group of companies
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology
Reference15 articles.
1. Vyvanse®, Package insert; https://www.accessdata.fda.gov/scripts/cder/daf/.
2. Elvanse®, Summary of product characteristics; https://www.medicines.org.uk/.
3. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers;Krishnan;Clin Drug Invest,2008
4. A Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and caucasian healthy adult subjects;James;Neuropsychopharmacol Rep,2020
5. Urinary excretion of d-amphetamine following oral doses in humans: implications for urine drug testing;Poklis;J Anal Toxicol,1998